Brii Biosciences Collaborates with Qpex to Develop and Commercialize Antibiotics for Drug-Resistant Infections in China

Shots:

• Qpex Biopharm to receive up front, development, regulatory and commercial milestones with royalties on sales in the licensed territories. Brii Biosciences to get the license to develop, manufacture, and commercialize Qpex’s antibiotic portfolio in China including Taiwan, Hong Kong, Macau and the People’s Republic of China
• The Qpex’s portfolio includes OMNIvance, ORAvance and a next-generation Polymyxin to treat MDR gram-negative infections. The companies will share the global development cost of the products
•  OMNIvance and ORAvance utilizes Qpex’s beta-lactamase inhibitor QPX7728 that inhibits both serine and metallo beta-lactamases, while next-generation polymyxin (IV) targets spectrum synthetic polymyxin with enhanced therapeutic profile addressing the infection caused by Pseudomonas and Acinetobacter

Click here to­ read full press release/ article | Ref: PRNewswire | Image: Brii Biosciences